Search

Displaying results 5881 - 5890 of 10000 in total
  1. Drug

    Cerulenin

    go.drugbank.com/drugs/DB01034
    Experimental

    In fatty acid synthesis, reported to bind in equimolar ratio to b-keto-acyl-ACP synthase. In sterol synthesis, inhibits HMG-CoA synthetase activity. … It is also shown to inhibit feeding and induce dramatic weight loss in mice. It is found naturally in the Cephalosporium caerulensfungus.

  2. Drug

    Nabiximols

    go.drugbank.com/drugs/DB14011
    Investigational

    In Canada, Sativex® has received a Notice of Compliance (NOC) for use as an as adjunctive treatment for symptomatic relief of spasticity in patients with multiple sclerosis (MS) who have not responded … This activity results in the well-known effects of smoking cannabis such as increased appetite, reduced pain, and changes in emotional and cognitive processes.

  3. Drug

    Telenzepine

    go.drugbank.com/drugs/DB19508
    Investigational

    Telenzepine has a monoisotopic molecular weight of 370.15 Da. … Telenzepine is under investigation in clinical trial NCT01155531 (Safety & Tolerability of a Combination of Antidepressant and Peptic Ulcer Drug in Overweight Healthy Subjects).

  4. Drug

    Setileuton

    go.drugbank.com/drugs/DB19550
    Investigational

    Setileuton is under investigation in clinical trial NCT00404313 (The Effect of MK0633 in Patients With Chronic Asthma (0633-007)). Setileuton has a monoisotopic molecular weight of 463.12 Da. … The usage of the INN stem '-leuton' in the name indicates that Setileuton is a 5-lipo-oxygenase inhibitor, anti-inflammatory.

  5. Drug

    Felezonexor

    go.drugbank.com/drugs/DB21067
    Investigational

    Felezonexor has a monoisotopic molecular weight of 419.12 Da. … Felezonexor is under investigation in clinical trial NCT02667873 (A Trial of a Novel XPO1 Inhibitor in Participants With Advanced Solid Tumors).

  6. Drug

    Icovamenib

    go.drugbank.com/drugs/DB21669
    Investigational

    Icovamenib is under investigation in clinical trial NCT06152042 (Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus). Icovamenib has a monoisotopic molecular weight of 566.28 Da. … The usage of the INN stem '-menib' in the name indicates that Icovamenib is a menin interaction inhibitor.

  7. Drug

    Nandrolone phenpropionate

    go.drugbank.com/drugs/DB00984
    ApprovedIllicit

    It is a schedule III drug in the U.S.

  8. Drug

    Trastuzumab emtansine

    go.drugbank.com/drugs/DB05773
    ApprovedInvestigational

    Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent … Trastuzumab emtansine is marketed under the brand name Kadcyla and is indicated for use in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic

  9. Drug

    Bethanechol

    go.drugbank.com/drugs/DB01019
    Approved

    Bethanechol is a synthetic ester that was initially synthesized in 1935. … An advantage of bethanechol is that in contrast to acetylcholine, bethanechol is not degraded by cholinesterase allowing its effects to be longer-lasting.[L32539]

    Synonyms: 2-(carbamoyloxy)-N,N,N-trimethylpropan-1-aminium
  10. Drug

    Xiliertinib

    go.drugbank.com/drugs/DB21453
    Investigational

    Xiliertinib is under investigation in clinical trial NCT02601274 (Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor). Xiliertinib has a monoisotopic molecular weight of 442.21 Da. … The usage of the INN stem '-ertinib' in the name indicates that Xiliertinib is a epidermal growth factor receptor (EGFR) inhibitor.